Equity ETF ChannelBiotech ETFs Make Gains Tuesday, Despite the J&J Vaccine PauseBy Ian YoungApril 13, 2021
Leveraged & Inverse ChannelPILL Hasn’t Been a Bitter ETF to Swallow The Past MonthBy Ben HernandezDecember 23, 2020
Beyond Basic Beta Channel4 ETFs to Consider with Big Pharma on the Senate’s Hot SeatBy Ben HernandezApril 9, 2019
